Azilsartan Medoxomil
|
|
|
- CAS-Nr.
- 863031-21-4
- Englisch Name:
- Azilsartan Medoxomil
- Synonyma:
- TAK 491;Azilsartan MedoxiMil;CS-306;Azizartan ester;Azilsaran medoxomil;Azilsartan medoxomil;Azilsartan MedoxoMil(TAK 491);Azilsartan Kamedoxomil Form I;Azilsartan Medoxomil USP/EP/BP;Azilsartan Acid Medoxomil Ester
- CBNumber:
- CB32516566
- Summenformel:
- C30H24N4O8
- Molgewicht:
- 568.53
- MOL-Datei:
- 863031-21-4.mol
|
Azilsartan Medoxomil Eigenschaften
- Schmelzpunkt:
- 160-161oC
- Dichte
- 1.45
- storage temp.
- Refrigerator
- Löslichkeit
- DMSO (Slightly), Methanol (Slightly, Heated, Sonicated)
- pka
- 6.99±0.20(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Light Beige
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitsschädlich bei Verschlucken. |
Akute Toxizität oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizität (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach Möglichkeit entfernen. Weiter spülen. |
|
Azilsartan Medoxomil Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Azilsartan medoxomil (Edarbi), an angiotensin II receptor antagonist,
was approved by the U.S. FDA in February 2011 for the treatment of
hypertension in adults. The discovery of azilsartan was the result
of a medicinal chemistry effort to identify an ARB with a different carboxylic
acid isostere than the ones found in the marketed ARBs. Several of the
marketed ARBs use a tetrazole group as a carboxylic acid isostere. The medicinal
chemistry approach that led to azilsartan involved the replacement of
this commonly used tetrazole with a 5-oxo-1,2,4-oxadiazole group.
Azilsartan can be synthesized by Suzuki coupling of p-tolyl boronic acid
to 2-bromobenzonitrile, followed by bromination of the methyl group.
The bromide is displaced to introduce a protected 2-ethoxy-1H-benzo[d]
imidazole-7-carboxylate. The cyano group is converted to a hydroxylamidine,
followed by reaction with an alkyl-chloroformate and intramolecular
cyclization to form the 5-oxo-1,2,4-oxadiazole ring. The acid is
then deprotected and converted to a prodrug. The parent, azilsartan has been
extensively characterized in vitro and compared with other marketed AT1
antagonists olmesartan, valsartan, telmisartan, irbesartan, and candesartan.
Azilsartan was found to be a potent (IC
50=2.6 nM), selective, inverse agonist
of the AT
1 receptor. From washout experiments, azilsartan was found
have slow dissociation from the receptor and thus is characterized as an insurmountable
antagonist.
Definition
ChEBI: A carboxylic ester obtained by formal condensation of the carboxy group of azilsartan with the hydroxy group of 4-(hydroxymethyl)-5-methyl-1,3-dioxol-2-one. A prodrug for azilsartan, it is used for treatment of hypertension.
Azilsartan Medoxomil Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Azilsartan Medoxomil Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 250)Lieferanten
- 1H-BenziMidazole-7-carboxylic acid, 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]Methyl]-2-ethoxy-, (5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl ester
- Azilsaran medoxomil
- (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-+oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
- 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzim
- 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
- Azilsartan medoxomil
- Azilsartan MedoxoMil(TAK 491)
- (5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]Methyl)-1H-benziMidazole-7-carboxylate
- CS-306
- azilsartan medoxomil 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
- Azilsartan Acid Medoxomil Ester
- Azilsartan Kamedoxomil Form I
- Azilsartan Medoxomil USP/EP/BP
- (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate
- Azilsartan medoxomilQ: What is
Azilsartan medoxomil Q: What is the CAS Number of
Azilsartan medoxomil Q: What is the storage condition of
Azilsartan medoxomil Q: What are the applications of
Azilsartan medoxomil
- Azizartan ester
- Azilsartan MedoxiMil
- TAK 491
- (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate
- (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate
- 863031-21-4
- C30H24N4O8
- Azilsartan Medoxomil
- Inhibitors
